ADAOBI ADIMORAH: Open Payments
NPI 1114429719 · PALM DESERT, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,038 in 107 payments from 9 companies in 2025. Trend: 2023 $51 · 2024 $577 · 2025 $2,038
Food & beverage: $2,038
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 38 | $631 |
| ABBVIE INC. | 21 | $318 |
| Janssen Pharmaceuticals, Inc | 18 | $316 |
| Neurocrine BioSciences, Inc. | 11 | $193 |
| Teva Pharmaceuticals USA, Inc. | 10 | $182 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $130 |
| Vanda Pharmaceuticals Inc. | 1 | $122 |
| Alkermes, Inc. | 4 | $83 |
| Lundbeck LLC | 3 | $63 |
Products named: REXULTI, VRAYLAR, INVEGA SUSTENNA, INGREZZA, ABILIFY MAINTENA, CAPLYTA, FANAPT, ABILIFY ASIMTUFII.
Industry payments across CA — which companies pay providers there.
